174 related articles for article (PubMed ID: 34918589)
1. Healthcare costs of colorectal cancer screening and events following colonoscopy among commercially insured average-risk adults in the United States.
Fisher DA; Princic N; Miller-Wilson LA; Wilson K; Limburg P
Curr Med Res Opin; 2022 Mar; 38(3):427-434. PubMed ID: 34918589
[TBL] [Abstract][Full Text] [Related]
2. Costs of colorectal cancer screening with colonoscopy, including post-endoscopy events, among adults with Medicaid insurance.
Fisher DA; Princic N; Miller-Wilson LA; Wilson K; Limburg P
Curr Med Res Opin; 2022 May; 38(5):793-801. PubMed ID: 35243953
[TBL] [Abstract][Full Text] [Related]
3. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
6. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
[No Abstract] [Full Text] [Related]
7. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
8. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
[TBL] [Abstract][Full Text] [Related]
9. Utilization of a Colorectal Cancer Screening Test Among Individuals With Average Risk.
Fisher DA; Princic N; Miller-Wilson LA; Wilson K; Fendrick AM; Limburg P
JAMA Netw Open; 2021 Sep; 4(9):e2122269. PubMed ID: 34473259
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer screening uptake and adherence by modality at a large tertiary care center in the United States: a retrospective analysis.
Cheney C; Parish A; Niedzwiecki D; Oko C; Walters C; Halpern D; Helmueller L; Hoyek NE; Miller-Wilson LA; Sullivan BA
Curr Med Res Opin; 2024 Mar; 40(3):431-439. PubMed ID: 38197407
[TBL] [Abstract][Full Text] [Related]
12. Patterns of initial colorectal cancer screenings after turning 50 years old and follow-up rates of colonoscopy after positive stool-based testing among the average-risk population.
Austin G; Kowalkowski H; Guo Y; Miller-Wilson LA; DaCosta Byfield S; Verma P; Housman L; Berke E
Curr Med Res Opin; 2023 Jan; 39(1):47-61. PubMed ID: 36017620
[TBL] [Abstract][Full Text] [Related]
13. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
[TBL] [Abstract][Full Text] [Related]
14. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
Prince M; Lester L; Chiniwala R; Berger B
World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
[TBL] [Abstract][Full Text] [Related]
15. Incident colorectal cancer screening and associated healthcare resource utilization and Medicare cost among Medicare beneficiaries aged 66-75 years in 2016-2018.
Li S; Miller-Wilson LA; Guo H; Hoover M; Fisher DA
BMC Health Serv Res; 2022 Oct; 22(1):1228. PubMed ID: 36192728
[TBL] [Abstract][Full Text] [Related]
16. The health economic impact of varying levels of adherence to colorectal screening on providers and payers.
Hathway JM; Miller-Wilson LA; Yao W; Jensen IS; Weinstein MC; Parks PD
J Med Econ; 2021; 24(1):69-78. PubMed ID: 33970747
[TBL] [Abstract][Full Text] [Related]
17. Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.
Finney Rutten LJ; Jacobson RM; Wilson PM; Jacobson DJ; Fan C; Kisiel JB; Sweetser S; Tulledge-Scheitel SM; St Sauver JL
Mayo Clin Proc; 2017 May; 92(5):726-733. PubMed ID: 28473037
[TBL] [Abstract][Full Text] [Related]
18. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
19. National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences.
Zhu X; Parks PD; Weiser E; Fischer K; Griffin JM; Limburg PJ; Finney Rutten LJ
Cancer Prev Res (Phila); 2021 May; 14(5):603-614. PubMed ID: 33888515
[TBL] [Abstract][Full Text] [Related]
20. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model.
Fisher DA; Saoud L; Finney Rutten LJ; Ozbay AB; Brooks D; Limburg PJ
Curr Med Res Opin; 2021 Jun; 37(6):1005-1010. PubMed ID: 33769894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]